Key result
CYP2C19 LoF alleles are linked to higher major cardiovascular events risk in clopidogrel-treated ACS patients undergoing PCI.
Why the study?
Does the CYP2C19 LoF allele increase the risk of MACE in ACS patients undergoing PCI and treated with clopidogrel?
Does the CYP2C19 LoF allele increase the risk of MACE in ACS patients undergoing PCI and treated with clopidogrel?
The presence of the CYP2C19 LoF allele significantly increases the risk of MACE in ACS patients receiving clopidogrel post-PCI, supporting the consideration of alternative antiplatelet therapies in this population.
Answers are grounded in this paper and cite their sources.
Supports CYP2C19-guided therapy in ACS-PCI; extends meta-analytic evidence but low-certainty data leave practice change open.
LoF alleles, who underwent PCI and were treated with clopidogrel were correlated with significantly increased risk of MACE compared with noncarriers.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2022) studied this question. CYP2C19 LoF alleles were associated with a increased risk of major cardiovascular events compared with noncarriers in clopidogrel-treated ACS patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: